Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749111 | 0.73 | MAPT (0.39) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL24813878 | 0.70 | MAPT (0.36) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL24737152 | 0.70 | NOS1 (0.41) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL2766813 | 0.69 | KMT2A (0.48) | MAPTRAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL21166137 | 0.67 | MAPT (0.34) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL21581037 | 0.65 | ALDH1A1 (0.33) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL6573388 | 0.64 | — | — | |
| SCHEMBL21732638 | 0.63 | RIPK2 (0.35) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL24884220 | 0.63 | NOS1 (0.35) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL20830859 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266911-B1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-6881802-B2 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1266911-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | BRAP, MCM4, BOLA2; BOLA2B | MAPT 749/4885RAB9A 3554/4885NPC1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.